• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet.

    The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Creatd as a significant shareholder in VTAK.

    The NYSE-listed VTAK equity becomes part of Creatd's growing portfolio of public and private positions across diversified industries, supported by its technology and AI-first operational infrastructure. Creatd helps companies overcome structural hurdles and mature into institutionally viable enterprises.

    Creatd acquired Flyte approximately one year ago, after initiating due diligence in Q4 2024, and implemented a disciplined turnaround strategy built around operational optimization, technology integration, and targeted revenue growth, while positioning the company for acquisition by a nationally-listed platform.

    Creatd initially acquired its position in Flyte using a combination of financing and its then OTC Pink Sheet common stock, whereas the premium exit consideration consists of cash and preferred equity in a New York Stock Exchange-listed company.

    "Creatd will continue to pursue its own national exchange listing strategy this year. The plan is to do so without relying on the traditional financing structures that often accompany those transactions. Typically those structures consume companies that have not first generated their own balance sheet value," said Jeremy Frommer, Chairman and CEO of Creatd, Inc. "Our recent reverse split, completed without an accompanying financing, was an important step toward meeting those national exchange listing requirements. This asset sale now provides the capital needed to complete the next phase."

    "Our balance sheet value is created through acquisition and incubation strategies for exchange-listed entities, where operating businesses can develop and position themselves for long term success. At the same time, Creatd is building value from a portfolio of investments that leverage proprietary technology and process."

    "Creatd represents one of the few turnaround-focused publicly traded platforms in the small-cap and micro-cap M&A space. We intend to institutionalize this model as we expand and broaden our company's platform," continued Frommer.

    "We also see a significant opportunity to address the structural gap created by the contraction of the middle market over the past two decades. Too many public companies today lack the infrastructure and support needed to reach their full potential. We are building a platform that helps companies stabilize, scale, and ultimately reach national exchange listings while creating lasting value."

    Creatd and VTAK will continue to collaborate through their strategic relationship, including ongoing efforts in aviation and eVTOL logistics platform development. The Company is grateful for the continued support of its shareholders throughout its multi-year transition and remains focused on executing its plan.

    About Creatd:

    Creatd, Inc. (OTCQB:CRTDD) acquires and grows technology-driven companies in aviation, media, and advisory services. Through its shared services model, Creatd enables its portfolio companies to scale efficiently, improve margins, and expand market reach. For more information, visit www.creatd.com.

    About Flyte: 

    Flyte is a technology-enabled regional air mobility company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter.

    Flight operations are conducted through Flyte's related entity, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.

    For more information, visit: www.flyte.travel

    Contact: [email protected]

    Forward-Looking Statements:

    This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business and our expectations with respect to the completion of the offering, the satisfaction of customary closing conditions related to the offering and the additional closings, the anticipated use of proceeds therefrom, and other statements that are predictive in nature. These statements can be identified often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects," and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Such factors and risks include, among others, market and other risks, that the additional closings after today may not occur if certain closing conditions are not met, and that there can be no assurance that the Company will successfully uplist to a national securities exchange. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release contains forward-looking statements and is qualified in its entirety by, and should be read together with, the cautionary statements, risk factors and other disclosures contained in the Company's filings with the SEC and OTC Markets.

    Source: CREATD INC.



    Primary Logo

    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.

    Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL CommercializationFORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced that it has completed the acquisition of the remaining 80.02% equity interest in Fly Flyte, Inc. ("Flyte") from Creatd, Inc. (OTCQB:CRTDD), resulting in 100% ownership of the AI-enabled regional aviation operator. The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the ow

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth

    FORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (NYSE:VTAK), a leader in advanced electrophysiology solutions, today announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer. Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform. Strategic Rationale Focus our capital allocation on core cardiac arrhythmia technologiesStrengthened balance sheetSimplified operating structure with enhanced strategic clarit

    2/19/26 8:15:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    2/18/26 4:16:13 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    1/20/26 4:20:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Director Caruso James Joseph converted options into 41 shares, increasing direct ownership by 456% to 50 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:54:19 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/9/26 5:06:37 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/12/26 4:15:59 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/6/26 5:25:30 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

    FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

    5/14/25 4:30:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care